Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Our CompaniesNewsroomInsights

About PPF Group

About UsPeople and statutory bodiesFinancial results & statementsReports and documents

Social responsibility

Social responsibilitySustainability
For MediaContactsCareers
cs

News to Email

Get the latest press releases, interviews, podcasts, and insights. 

Subscribe To News

Follow us

For Media

  • Press Releases
  • Interviews and Podcasts
  • Subscribe To News
  • Downloads
  • Contacts

MAY BE OF INTEREST

  • Our Companies
  • Newsroom
  • Insights

Contacts

  • PPF Group Companies
  • Terms of use
  • Data protection
  • Sitemap
  • Cookies policy

2026 © PPF Group

Most often you are looking for

Annual ReportsInsightsVisions and StrategiesPress Releases
  • Insights

  • Biotech Market / Business Intelligence

  • February 2025 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions

Legal Notice

Sotio Biotech

2/4/2025 | 1 minute to read

Print
Copy link

Share on social networks

Share on social networks

Print

Copy link

Related articles

Sotio Biotech

2/4/2025

First rounds of FDA layoffs led by the new Health Secretary form uncertain environment

Sotio Biotech

2/4/2025

Odronextamab BLA accepted for FDA review for the treatment of follicular lymphoma

Sotio Biotech

2/4/2025

Cargo Therapeutics discontinued its CAR-T treatment firi-cel in Phase 2 study of firi-cel

Sotio Biotech

2/4/2025

FDA approved Adcetris for treatment of patients with large B-cell lymphoma

Sotio Biotech

2/4/2025

ImmunityBio and Beigene to run Phase 3 of Anktiva plus PD-1 in NSCLC

Sotio Biotech

15/8/2025

Legal Notice 5/2025

Sotio Biotech

19/8/2025

Trump demands pharmas provide “most favored nation pricing” for Medicaid drugs

Insights

The material contained in this document was prepared based on information from public and private sources that SOTIO believes to be reliable. It is protected by copyright law and cannot be further disseminated or used for any commercial purposes without SOTIO´s prior written consent. 

This document is distributed for general informational and educational purposes only and is not intended to constitute legal or investment advice. The information, opinions and views contained herein have not been tailored to the investment objectives of any one individual, are current only as of the date hereof and may be subject to change at any time without prior notice. SOTIO does not have any obligation to provide revised opinions in the event of changed circumstances. All investment strategies and investments involve risk of loss. 

Nothing contained in this document should be construed as investment advice. Any reference to an investment’s past or potential performance is not, and should not be construed as, a recommendation or as a guarantee of any specific outcome or profit. 

The information contained herein is not, and shall not constitute an offer to sell, a solicitation of an offer to buy or an offer to purchase any securities, nor should it be deemed to be an offer, or a solicitation of an offer, to purchase or sell any investment product or service.